239 related articles for article (PubMed ID: 24998704)
1. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life.
Peters M; Maenhout M; van der Voort van Zyp JR; Moerland MA; Moman MR; Steuten LM; van Deursen MJ; van Vulpen M
Radiother Oncol; 2014 Jul; 112(1):77-82. PubMed ID: 24998704
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
[TBL] [Abstract][Full Text] [Related]
3. MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study.
Peters M; van Son MJ; Moerland MA; Kerkmeijer LGW; Eppinga WSC; Meijer RP; Lagendijk JJW; Shah TT; Ahmed HU; van der Voort van Zijp JRN
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1045-1053. PubMed ID: 30926575
[TBL] [Abstract][Full Text] [Related]
4. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.
Rose JN; Crook JM; Pickles T; Keyes M; Morris WJ
Brachytherapy; 2015; 14(3):342-9. PubMed ID: 25727178
[TBL] [Abstract][Full Text] [Related]
5. Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer.
Maenhout M; Peters M; van Vulpen M; Moerland MA; Meijer RP; van den Bosch MAAJ; Nguyen PL; Frank SJ; van der Voort van Zyp JRN
Technol Cancer Res Treat; 2017 Dec; 16(6):1194-1201. PubMed ID: 29333958
[TBL] [Abstract][Full Text] [Related]
6. Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review.
Peters M; Moman MR; van der Poel HG; Vergunst H; de Jong IJ; Vijverberg PL; Battermann JJ; Horenblas S; van Vulpen M
World J Urol; 2013 Apr; 31(2):403-9. PubMed ID: 22903773
[TBL] [Abstract][Full Text] [Related]
7. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
[TBL] [Abstract][Full Text] [Related]
8. Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer.
Peters M; van der Voort van Zyp JRN; Moerland MA; Hoekstra CJ; van de Pol S; Westendorp H; Maenhout M; Kattevilder R; Verkooijen HM; van Rossum PSN; Ahmed HU; Shah TT; Emberton M; van Vulpen M
Brachytherapy; 2016; 15(3):296-305. PubMed ID: 26948662
[TBL] [Abstract][Full Text] [Related]
9. Salvage I seed implantation for prostate cancer with postradiation local recurrence.
Shimbo M; Inoue K; Koike Y; Katano S; Kawashima K
Urol Int; 2013; 90(3):294-300. PubMed ID: 23467122
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.
Lee B; Shinohara K; Weinberg V; Gottschalk AR; Pouliot J; Roach M; Hsu IC
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1106-12. PubMed ID: 17197119
[TBL] [Abstract][Full Text] [Related]
11. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
12. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
[TBL] [Abstract][Full Text] [Related]
13. F-SHARP: a Phase I/II trial of focal salvage high-dose-rate brachytherapy for Radiorecurrent prostate cancer.
Solanki AA; Yoo RK; Adams W; Davicioni E; Mysz ML; Shea S; Gupta GN; Showalter T; Garant A; Hentz C; Farooq A; Baldea K; Small W; Harkenrider MM
BJU Int; 2024 Feb; 133(2):188-196. PubMed ID: 37562825
[TBL] [Abstract][Full Text] [Related]
14. Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer.
Chitmanee P; Tsang Y; Tharmalingam H; Hamada M; Alonzi R; Ostler P; Hughes R; Lowe G; Hoskin P
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):259-265. PubMed ID: 31708350
[TBL] [Abstract][Full Text] [Related]
15. A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy.
Yamada Y; Kollmeier MA; Pei X; Kan CC; Cohen GN; Donat SM; Cox BW; Zelefsky MJ
Brachytherapy; 2014; 13(2):111-6. PubMed ID: 24373762
[TBL] [Abstract][Full Text] [Related]
16. Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.
Henríquez I; Sancho G; Hervás A; Guix B; Pera J; Gutierrez C; Abuchaibe O; Martínez-Monge R; Tormo A; Polo A
Radiat Oncol; 2014 Apr; 9():102. PubMed ID: 24885287
[TBL] [Abstract][Full Text] [Related]
17. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.
Chen CP; Weinberg V; Shinohara K; Roach M; Nash M; Gottschalk A; Chang AJ; Hsu IC
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):324-9. PubMed ID: 23474112
[TBL] [Abstract][Full Text] [Related]
18. [Salvage 125I brachytherapy of locally recurrent prostate cancer].
Gesztesi L; Ágoston P; Major T; Gődény M; Andi J; Lengyel Z; Polgár C
Magy Onkol; 2014 Sep; 58(3):219-24. PubMed ID: 25260087
[TBL] [Abstract][Full Text] [Related]
19. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
20. Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy.
Peters M; van der Voort van Zyp JR; Moerland MA; Hoekstra CJ; van de Pol S; Westendorp H; Maenhout M; Kattevilder R; Verkooijen HM; van Rossum PS; Ahmed HU; Shah TT; Emberton M; van Vulpen M
Radiother Oncol; 2016 Apr; 119(1):104-10. PubMed ID: 26897512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
